These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 17901249)

  • 21. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
    Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
    Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.
    Olson LE; Roper RJ; Sengstaken CL; Peterson EA; Aquino V; Galdzicki Z; Siarey R; Pletnikov M; Moran TH; Reeves RH
    Hum Mol Genet; 2007 Apr; 16(7):774-82. PubMed ID: 17339268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.
    Reynolds LE; Watson AR; Baker M; Jones TA; D'Amico G; Robinson SD; Joffre C; Garrido-Urbani S; Rodriguez-Manzaneque JC; Martino-Echarri E; Aurrand-Lions M; Sheer D; Dagna-Bricarelli F; Nizetic D; McCabe CJ; Turnell AS; Kermorgant S; Imhof BA; Adams R; Fisher EM; Tybulewicz VL; Hart IR; Hodivala-Dilke KM
    Nature; 2010 Jun; 465(7299):813-7. PubMed ID: 20535211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematologic disorders in 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome.
    Dewald GW; Diez-Martin JL; Steffen SL; Jenkins RB; Stupca PJ; Burgert EO
    Am J Med Genet Suppl; 1990; 7():247-50. PubMed ID: 2149957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Mmu17 Non-Hsa21 Orthologous Genes in the Ts65Dn Mouse Model of Down Syndrome: The Gold Standard Refuted.
    Guedj F; Kane E; Bishop LA; Pennings JLA; Herault Y; Bianchi DW
    Biol Psychiatry; 2023 Jul; 94(1):84-97. PubMed ID: 37074246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perinatal loss of Ts65Dn Down syndrome mice.
    Roper RJ; St John HK; Philip J; Lawler A; Reeves RH
    Genetics; 2006 Jan; 172(1):437-43. PubMed ID: 16172497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developmental instability of the cerebellum and its relevance to Down syndrome.
    Shapiro BL
    J Neural Transm Suppl; 2001; (61):11-34. PubMed ID: 11771737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome.
    Carmichael CL; Majewski IJ; Alexander WS; Metcalf D; Hilton DJ; Hewitt CA; Scott HS
    Blood; 2009 Feb; 113(9):1929-37. PubMed ID: 19109561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome.
    Duchon A; Raveau M; Chevalier C; Nalesso V; Sharp AJ; Herault Y
    Mamm Genome; 2011 Dec; 22(11-12):674-84. PubMed ID: 21953411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penetrance of Congenital Heart Disease in a Mouse Model of Down Syndrome Depends on a Trisomic Potentiator of a Disomic Modifier.
    Li H; Edie S; Klinedinst D; Jeong JS; Blackshaw S; Maslen CL; Reeves RH
    Genetics; 2016 Jun; 203(2):763-70. PubMed ID: 27029737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia.
    Gialesaki S; Bräuer-Hartmann D; Issa H; Bhayadia R; Alejo-Valle O; Verboon L; Schmell AL; Laszig S; Regényi E; Schuschel K; Labuhn M; Ng M; Winkler R; Ihling C; Sinz A; Glaß M; Hüttelmaier S; Matzk S; Schmid L; Strüwe FJ; Kadel SK; Reinhardt D; Yaspo ML; Heckl D; Klusmann JH
    Blood; 2023 Mar; 141(10):1105-1118. PubMed ID: 36493345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome.
    Lyle R; Gehrig C; Neergaard-Henrichsen C; Deutsch S; Antonarakis SE
    Genome Res; 2004 Jul; 14(7):1268-74. PubMed ID: 15231743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.
    Malinge S; Izraeli S; Crispino JD
    Blood; 2009 Mar; 113(12):2619-28. PubMed ID: 19139078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.
    Billingsley CN; Allen JR; Baumann DD; Deitz SL; Blazek JD; Newbauer A; Darrah A; Long BC; Young B; Clement M; Doerge RW; Roper RJ
    Am J Med Genet A; 2013 Aug; 161A(8):1866-74. PubMed ID: 23843306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models.
    Galdzicki Z; Siarey R; Pearce R; Stoll J; Rapoport SI
    Brain Res Brain Res Rev; 2001 Apr; 35(2):115-45. PubMed ID: 11336779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome.
    Cataldo AM; Petanceska S; Peterhoff CM; Terio NB; Epstein CJ; Villar A; Carlson EJ; Staufenbiel M; Nixon RA
    J Neurosci; 2003 Jul; 23(17):6788-92. PubMed ID: 12890772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.
    Blazek JD; Gaddy A; Meyer R; Roper RJ; Li J
    Bone; 2011 Feb; 48(2):275-80. PubMed ID: 20870049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
    Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
    Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.
    Belichenko NP; Belichenko PV; Kleschevnikov AM; Salehi A; Reeves RH; Mobley WC
    J Neurosci; 2009 May; 29(18):5938-48. PubMed ID: 19420260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.